Marinus Pharma (MRNS) Reports Q4, Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- UBS Reiterates Buy Rating on Snowflake Inc. (SNOW)
Marinus Pharma (MRNS) Reports In-Line Q4 EPS
March 21, 2022 7:25 AM EDTMarinus Pharma (NASDAQ: MRNS) reported Q4 EPS of ($0.77), in-line with the analyst estimate of ($0.77). Revenue for the quarter came in at $1.52 million versus the consensus estimate of $3.46 million.
For earnings history and earnings-related data on Marinus Pharma (MRNS) click here.
... More